trending Market Intelligence /marketintelligence/en/news-insights/trending/VJeIvxjOnixpxUYPQLDFyw2 content esgSubNav
In This List

Pharmarise fiscal Q1 profit falls YOY

Blog

Using ESG Analysis to Support a Sustainable Future

Video

S&P Capital IQ Pro | Powered by Expert Insights

Blog

Q&A: Streamlining Analytics for TCFD Reporting

Blog

Evergrande and the wider impact: a sentiment analytics based perspective


Pharmarise fiscal Q1 profit falls YOY

Pharmarise Holdings Corp. said its normalized net income for the fiscal first quarter ended Aug. 31 came to ¥6.13 per share, a decline of 76.4% from ¥26.00 per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was ¥55.1 million, a decrease of 71.7% from ¥195.0 million in the year-earlier period.

The normalized profit margin fell to 0.6% from 2.1% in the year-earlier period.

Total revenue rose on an annual basis to ¥9.44 billion from ¥9.14 billion, and total operating expenses grew 6.1% year over year to ¥9.29 billion from ¥8.76 billion.

Reported net income came to a loss of ¥11.0 million, or a loss of ¥1.22 per share, compared to income of ¥140.0 million, or ¥18.67 per share, in the year-earlier period.

As of Oct. 15, US$1 was equivalent to ¥106.21.